<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04861415</url>
  </required_header>
  <id_info>
    <org_study_id>2734</org_study_id>
    <nct_id>NCT04861415</nct_id>
  </id_info>
  <brief_title>SBRT vs. Conventional Fractionation With HDR Boost for Prostate Cancer</brief_title>
  <acronym>SHARP</acronym>
  <official_title>A Randomized Feasibility Trial of Stereotactic Body Radiotherapy Versus Conventional Fractionation With High Dose-rate (HDR) Brachytherapy Boost for Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Gerard Morton</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Random assignment between SBRT and conventionally fractionated boost following HDR&#xD;
      brachytherapy for prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many treatment options exist for prostate cancer. One common treatment approach is to combine&#xD;
      high-dose rate (HDR) brachytherapy (temporary insertion of radiation into the prostate) and&#xD;
      external beam radiation. External beam radiation typically requires daily radiation treatment&#xD;
      for three to five weeks. Improvements to radiation planning and delivery has allowed&#xD;
      stereotactic body radiation therapy (SBRT) to be implemented in many types of cancer. SBRT&#xD;
      has been implemented as a standard treatment option after HDR brachytherapy in response to&#xD;
      the COVID pandemic. We are seeking to evaluate whether it is feasible to randomly assign men&#xD;
      between SBRT (which will be five treatments of radiation or conventional radiation (3-5 weeks&#xD;
      of daily treatment) following HDR brachytherapy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2020</start_date>
  <completion_date type="Anticipated">December 23, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 23, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Feasibility</measure>
    <time_frame>18mo - 2 years</time_frame>
    <description>The proportion of patients accepting of being randomized divided by the number of patients approached for the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QOL</measure>
    <time_frame>7 years</time_frame>
    <description>Urinary, bowel and sexual health-related quality of life measured by the Expanded Prostate Cancer Index Composite (EPIC) domains over the study period. Each domain is normalized from 0 to 100, with a higher score indicating better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Toxicity</measure>
    <time_frame>7 years</time_frame>
    <description>Proportion of patients with urinary, bowel and sexual Grade 2 and 3 toxicity measured by CTCAE v5.0 throughout the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative biochemical failure</measure>
    <time_frame>7 years</time_frame>
    <description>Defined as the time of enrolment to biochemical failure (based on the Phoenix definition, PSA nadir plus 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>7 years</time_frame>
    <description>Defined as time of enrollment to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer Free Survival</measure>
    <time_frame>7 years</time_frame>
    <description>Defined as time of enrolment to death attributed to prostate cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis Free Survival</measure>
    <time_frame>7 years</time_frame>
    <description>Defined as time of enrolment to development of metastasis or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Local Failure</measure>
    <time_frame>7 years</time_frame>
    <description>Defined as time of enrolment to first local recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Regional Failure</measure>
    <time_frame>7 years</time_frame>
    <description>Defined as time of enrolment to first regional recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADT Free Survival</measure>
    <time_frame>7 Years</time_frame>
    <description>Defined as time of enrolment to salvage ADT use or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA nadir</measure>
    <time_frame>6 years</time_frame>
    <description>PSA nadir at 4-years post treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Conventional Fractionated Radiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prostate Only Radiation - 37.5Gy in 15 daily fractions to the prostate and proximal/entire seminal vesicle&#xD;
Prostate + Nodal Radiation - 46Gy in 23 daily fractions to the prostate, seminal vesicle and regional lymph nodes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stereotactic Body Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prostate Only Radiation - 25Gy in 5 fractions to the prostate and proximal/entire seminal vesicle&#xD;
Prostate + Nodal Radiation - 25Gy in 5 fractions to the prostate, seminal vesicle and regional lymph nodes</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Sterotactic Body Radiotherapy</intervention_name>
    <description>Hypofractionated stereotactic radiation treatment.</description>
    <arm_group_label>Stereotactic Body Radiotherapy</arm_group_label>
    <other_name>SBRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Conventionally Fractionated Radiation</intervention_name>
    <description>External beam radiation therapy treatment</description>
    <arm_group_label>Conventional Fractionated Radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
          -  Informed consent for treatment and study participation completed&#xD;
&#xD;
          -  Pathologically proven diagnosis of prostate adenocarcinoma&#xD;
&#xD;
          -  ECOG Performance Status 0-2&#xD;
&#xD;
          -  No prior history of pelvic radiotherapy, brachytherapy, cryosurgery, HIFU, TURP or&#xD;
             radical prostatectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of nodal or distant metastasis on staging MRI or CT Abdomen/Pelvis and Bone&#xD;
             scan within 90 days of enrolment (CT/MRI/Bone Scan are only required if the clinical&#xD;
             risk of metastatic disease is sufficient to warrant these scans)&#xD;
&#xD;
          -  Plan for adjuvant chemotherapy post-radiotherapy&#xD;
&#xD;
          -  Serious medical comorbidities or other contraindications to HDR brachytherapy&#xD;
&#xD;
          -  Presence of inflammatory bowel disease&#xD;
&#xD;
          -  Presence of connective tissue disorder seen as a contraindication to radiotherapy&#xD;
&#xD;
          -  Medically unfit for general/spinal anesthesia&#xD;
&#xD;
          -  Unable or unwilling to complete questionnaires&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerard Morton</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerard Morton, MD</last_name>
    <phone>416-480-6100</phone>
    <phone_ext>6165</phone_ext>
    <email>gerard.morton@sunnybrook.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Merrylee McGuffin</last_name>
    <phone>416-480-6100</phone>
    <phone_ext>85454</phone_ext>
    <email>Merrylee.Mcguffin@sunnybrook.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerard Morton, MD, FRCPC</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>6165</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Merrylee McGuffin, MSc, MRT(T)</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>85454</phone_ext>
      <email>Merrylee.Mcguffin@sunnybrook.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Corkum</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2021</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sunnybrook Health Sciences Centre</investigator_affiliation>
    <investigator_full_name>Dr. Gerard Morton</investigator_full_name>
    <investigator_title>Radiation Oncologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

